Project Klinische Studie

Basic data

Title:
Klinische Studie
Duration:
15/03/2015 to 16/08/2016
Abstract / short description:
A randomized, double-blind, multicenter study to assess the efficacy and safety of 16 weeks secukinumab dosage interval shortening (2-weekly 300 mg s.c.) in comparison to continued standard treatment (4-weekly 300 mg s.c.) in patients with moderate-severe plaque type psoriasis who achieved less than clear or almost clear skin (PASI response ≥75 to PASI<90) after 16 weeks under the standard dose of secukinumab
Keywords:
clinical trial
klinische Studie
psoriasis
Schuppenflechte
dermatology
Dermatologie

Involved staff

Managers

Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Contact persons

Adamczyk, Annette
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine

Funders

Nürnberg, Bayern, Germany
Help

will be deleted permanently. This cannot be undone.